Epithalon: What It Is, Where to Get It Prescribed, and What It Costs

Epithalon is a tetrapeptide — four amino acids, sequence Ala-Glu-Asp-Gly, abbreviated AEDG — and one of the shortest peptides in clinical use. It was designed in the 1990s at the St Petersburg Institute of Bioregulation and Gerontology, a Russian institute led by Vladimir Khavinson, to reproduce the amino-acid composition of Epithalamin, a crude bovine pineal extract the same group had been giving to elderly patients since the Soviet era. That lineage is the key to reading the literature: much of the "human data" quoted online for Epithalon was generated with the extract, not the peptide. The pineal gland makes melatonin and sets the day–night rhythm, which is why circadian hormones and ageing are intertwined throughout the research.

The literature uses the three spellings interchangeably; the FDA's documents use "Epitalon." None is an official adopted name — the FDA's July 2026 briefing noted the compound has no USAN, INN or IUPAC name and no USP monograph, and that inconsistent naming across suppliers is itself a quality concern. "Epithalamin" is the original extract, a different thing, and the distinction matters every time a study is quoted.

It is not melatonin and it is not a sedative; nothing in the research describes a direct hypnotic effect. It is not a hormone. It is not a "telomere extender" in the marketing sense — the telomere findings are from cultured cells, and no one has measured telomere length in a person before and after a course. It is not a treatment for any diagnosed disease.

The finding that made the compound famous is a 2003 paper in the Bulletin of Experimental Biology and Medicine by Khavinson, Bondarev and Butyugov. Adding Epithalon to cultured human fetal fibroblasts — cells that do not normally express telomerase — induced the enzyme and lengthened telomeres, the protective caps on chromosome ends that shorten with each division. A companion paper the next year reported the treated cells dividing past their usual limit.

For two decades that single-laboratory result was all there was. In 2025 a group at Brunel University London published in Biogerontology the first independent replication: dose-dependent telomere lengthening in normal human epithelial and fibroblast lines through hTERT and telomerase upregulation. The same paper reported telomere extension in breast cancer cell lines by a different route. Telomerase induction is also, as the FDA pointed out in July 2026, the mechanism by which cells escape senescence, and long-term effects in a whole organism are unknown.

In 2001, Goncharova and colleagues at the Institute of Medical Primatology in Sochi reported that a short course of Epithalon in old female rhesus monkeys raised evening melatonin more than fourfold and lowered evening cortisol, restoring the day–night swing the old animals had lost; younger monkeys showed no change. A 2004 paper by Korkushko and colleagues reported the parent extract, Epithalamin, raising night-time melatonin in healthy elderly people whose pineal output was low, with little effect where output was normal.

The mechanism is not direct: a 2003 study in the Journal of Endocrinological Investigation by a Paris group working with Khavinson perfused rat pineal glands with the peptide and found no effect on melatonin secretion, and the FDA's 2026 review called the in-vivo mechanism unknown. The most recent human-facing work from St Petersburg, in Advances in Gerontology in 2020, reports a sublingual form altering expression of the clock genes Clock, Csnk1e and Cry2 in blood cells of middle-aged women with low melatonin output — a gene-expression readout, not a measure of sleep. Across the monkey, elderly and shift-worker work the effect appears where melatonin output is already low and is absent where it is normal.

A 2022 paper in Aging from a Chinese group reported Epithalon protecting mouse oocytes from oxidative damage in vitro, and a 2022 paper in the International Journal of Molecular Sciences described effects on inflammatory signalling in a human monocyte line. A 2025 review from the Medical University of Warsaw concludes, fairly, that it remains uncertain whether these mechanisms are the whole story.

The anchor study is Anisimov and colleagues, Biogerontology 2003. Female SHR mice received Epithalon in brief monthly courses from three months of age until natural death, 54 per group. Treatment did not change food intake, body weight or mean lifespan. It did slow the age-related shutdown of oestrous cycling, reduce chromosome aberrations in bone-marrow cells, and extend the lifespan of the last ten per cent of survivors by about 13 per cent. Overall tumour incidence was unchanged; leukaemia was less frequent. A 2007 paper by Vinogradova and colleagues extended the question to rats under disrupted lighting. The FDA noted a single fixed dose, female animals only, and intermittent exposure — useful, but not a toxicology package.

A 2002 paper in Neuro Endocrinology Letters reported the peptide preserving retinal function in rats with hereditary retinal degeneration and "a positive clinical effect" in patients with retinitis pigmentosa. The human part is an uncontrolled case series from the originating institute, included because it is frequently cited, not because it settles anything.

This is the source of the "extends human life" claims. In 2003, Khavinson and Morozov published in Neuro Endocrinology Letters a summary of 266 elderly patients followed for six to eight years in St Petersburg and Kiev, treated for the first two to three years with Thymalin (a thymus extract), Epithalamin (the pineal extract), or both. They reported fewer respiratory infections, less cardiovascular and musculoskeletal disease, and mortality 1.6- to 1.8-fold lower with Epithalamin alone.

Three things to hold in mind. The preparation was Epithalamin, not synthetic Epithalon; that the peptide reproduces the extract's effects is the group's inference. It was open-label, run by the institute that developed the products. And it was published as a summary, not a full trial report. A later randomised comparative study by Korkushko and colleagues (Bulletin of Experimental Biology and Medicine, 2011) followed 39 elderly coronary patients on repeated Epithalamin courses against 40 on standard care, with a fifteen-year follow-up, and reported slower cardiovascular ageing and lower mortality. It is the best-designed human study in the literature; it is also small, from the same network, and about the extract.

There are no randomised, placebo-controlled trials of injectable Epithalon in humans for any indication. What exists in people is: the elderly cohorts above, all with the Epithalamin extract; a small Russian-language randomised, placebo-controlled study of a sublingual spray in 75 women aged 40 to 50 working night shifts, in which 20 received the peptide for 20 days and showed a 1.7-fold rise in a urinary melatonin metabolite, with no sleep outcomes measured and blinding not specified; and the uncontrolled retinitis pigmentosa series. When the FDA reviewed the compound for insomnia in July 2026 it found no publication reporting efficacy in patients with insomnia and no study of the subcutaneous route at all.

The honest description is "extensively studied in cells and animals, with a human evidence base that is small, old, almost entirely from one research network in Russia and Ukraine, and largely generated with the parent extract." Much of what is written online quietly collapses those distinctions.

• It does not establish that Epithalon lengthens telomeres in a living person. No study has measured that.
• It does not establish an effect on human lifespan. The cohort data are from the extract, open-label, and from the originating institute.
• It does not establish an effect on sleep. A melatonin metabolite rose in one small study; sleep was not measured.
• It does not establish long-term safety in humans. The FDA found no pharmacokinetic data, no safety study and no adverse-event reports — an absence of data, not evidence of safety.
• It does not establish efficacy for any condition as an FDA-approved treatment. It is not approved for anything.

Most people notice nothing in the first fortnight, and that is expected rather than a sign the course is not working. The earliest thing anyone reports is a subtle change in sleep timing — sleepy earlier, waking more consistently. People whose rhythm is already regular are the least likely to notice anything.

This is the window a vial covers at Monday-through-Friday dosing, and where prescribers describe sleep-pattern effects settling in if they occur. The Russian work used short courses rather than continuous dosing, which is part of why the directions leave weekends off. Nothing about telomeres or ageing is observable in this window or any other; those are laboratory endpoints, not things you feel, and commercial telomere-length tests are too noisy to show anything.

There is no withdrawal and no rebound described in the literature. The Khavinson protocols were intermittent — courses separated by months — and prescribers generally follow that logic rather than treating Epithalon as an indefinite daily medication. Whether and when to repeat is your physician's call; the FDA's concern about continuous telomerase activation argues against improvising a permanent schedule.

The directions are written in millilitres and in insulin-syringe units because that is what you can actually read off the barrel. 0.25 mL is 25 units on a U-100 syringe. You are not calculating anything — the number is printed on your medication.

Subcutaneous means into the fat layer, not the muscle. Abdomen and thigh are the usual sites, rotated so the same spot is not used repeatedly. There is no argument for injecting near any particular body part; the mechanisms described are systemic. Time of day is worth asking your physician about, since the animal work involved shifts in evening hormone levels.

20 doses at Monday through Friday is four calendar weeks, which is why refills run on a 28-day cycle. The weekday-only pattern echoes the intermittent courses used in the research. One vial per fill, always — not a stockpile.

Refrigerated, and it ships that way in insulated packaging with ice packs. The FDA's briefing noted that reconstituted Epithalon is stable for only days at fridge temperature in the manufacturer's data, so the pharmacy's beyond-use date on the label governs. Beyond-use dating runs from first puncture.

Sister compounds from the same St Petersburg institute, studied together in the elderly cohorts. Thymalin derives from thymus tissue and is described around immune regulation; Epithalon derives from pineal tissue and is described around melatonin rhythm and telomerase. In the 2003 cohort the combination was reported to outperform either alone, which is why some physicians prescribe them in sequence. Both share the same evidence limitations.

Both get filed under "sleep peptides," but they aim differently. DSIP was named for an effect on sleep architecture in animals and has been studied for sleep as such. Epithalon's data concern the timing signal, melatonin, with no sleep endpoint measured. Falling or staying asleep points toward DSIP; a rhythm out of phase is the closer fit for Epithalon.

Identical Epithalon, different company in the vial. The ETERNAL blend pairs it with GHK-Cu, BPC-157 and TB-500, recovery and skin agents with their own literature. The single vial suits one variable at a time; the blend suits wanting the other three too. Neither is clinically superior.